1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited

APOLLOHOSP.NS
Apollo Hospitals Enterprise LimitedIN flagNational Stock Exchange of India
8,836.50
INR
-9.00
- -
1.27TMarket Cap
Apollo Hospitals Enterprise Limited
APOLLOHOSP.NS
(National Stock Exchange of India)

Recent

price

8,836.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
210.24
241.51
273.41
315.13
372.22
446.7
519.79
591.07
689.59
801.19
747.75
1,010.97
1,143.71
1,311.84
1,515.74
1,754.57
1,464.21
Revenue per Share
14.17
16.29
21.45
22.02
23.76
16.99
15.88
8.44
16.96
32.7
10.74
73.42
56.97
62.5
100.56
135.04
102.17
Basic EPS, GAAP
-6.03
-0.57
-15.78
-17.14
-28.62
-30.1
-3.66
-6.07
16.27
56.06
69.23
72.25
17.28
54.48
29.47
62.15
- -
Free Cash Flow per Basic Share
3.49
3.59
4.04
5.5
5.75
11.61
- -
7.25
6.02
11.15
2.74
3.01
17.75
15
19
20
- -
Dividend per Share
5.03
10.64
13.77
18.83
29.98
17.36
29.96
23.7
31.63
35.64
47.5
121.14
148.21
197.83
279.11
5
- -
Book Value per Share
142.28
180.55
187.56
202
224.71
219.7
215.18
210.7
217.05
220.59
310.11
337.67
378.31
429.28
510.01
605.26
- -
Tangible Book Value per Share
124
130
138
139
139
139
139
139
139
139
140
144
144
144
144
144
154
Basic Weighted Avg Shares
26,054
31,475
37,687
43,842
51,785
62,147
72,316
82,233
95,939
111,466
104,680
145,362
164,448
188,623
217,940
252,285
225,505
Sales/Revenue/Turnover
14.76
12.92
12.81
12
10.67
7.31
6.05
5.51
7.03
9.28
5.42
10.93
8.81
9.05
10.39
11.47
10.66
Operating Margin (%)
942
1,236
1,420
1,671
2,117
2,659
3,140
3,590
3,955
6,197
5,731
6,007
6,154
6,870
7,575
8,761
7,948
Depreciation Expense
1,755
2,122
2,957
3,063
3,306
2,364
2,210
1,174
2,360
4,549
1,504
10,556
8,191
8,986
14,459
19,417
15,735
Net Income, GAAP
33.41
35.27
26.32
25.02
28.55
29.17
40.96
65.27
46.54
34.12
38.38
30.23
22.4
32.27
26.19
24.74
25.6
Effective Tax Rate (%)
6.74
6.74
7.85
6.99
6.38
3.8
3.06
1.43
2.46
4.08
1.44
7.26
4.98
4.76
6.63
7.7
6.98
Profit Margin (%)
2,462
3,360
8,192
7,041
9,432
7,247
11,659
6,529
3,263
3,096
16,035
16,263
10,121
6,152
24,500
4,185
- -
Working Capital
7,480
5,744
10,789
12,224
18,577
24,498
29,534
29,238
29,521
47,196
37,036
37,605
34,359
42,170
43,858
51,004
- -
LT Debt
19,238
25,194
27,641
29,955
33,517
34,091
34,378
33,839
34,690
34,697
48,024
59,030
65,313
73,205
86,529
99,745
- -
Total Equity
9.47
8.54
9.71
9.47
8.1
5.55
4.08
2.39
5.26
8.54
3.93
11.93
10.99
10
12.72
13.48
- -
Return on Invested Capital (%)
21.53
25.54
29.75
24.93
19.03
12.26
13.07
7.02
10.41
14.92
7.35
22.19
16.1
14.84
18.72
23.44
35.74
Return on Capital (%)
199.25
211.13
180
135.59
97.36
71.79
67.15
31.46
61.32
97.21
25.91
87.72
42.3
36.12
42.17
95.06
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
10,334
- -
LT Borrowings
- -
19,719
- -
LT Finance Leases
- -
24,139
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
144
- -
Market Capitalization
1,049,145
1,018,921
1,115,348

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
70,289
- -
Cash, Cash Equivalents & STI
- -
20,104
- -
Accounts Receivable, Net
- -
30,161
- -
Inventories
- -
4,808
- -
Total Current Liabilities
- -
45,789
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
10,334
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.93%
15.82%
15.27%
Free Cash Flow
9.04%
42.3%
110.93%
Net Income, GAAP
75.78%
136.87%
34.29%
Sales/Revenue/Turnover
15.48%
19.6%
15.76%
Total Cash Common Dividend
- -
103.78%
5.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
44,178
48,469
48,506
47,470
188,623
2025
50,856
55,893
55,269
55,922
217,940
2026
58,421
64,774
66,055
- -
252,285

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.59
16.2
17.06
- -
62.5
2025
21.23
26.34
25.89
21.1
100.56
2026
30.1
34.94
36.82
- -
135.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
15
2025
- -
- -
- -
- -
19
2026
- -
- -
- -
- -
20
Similar Companies
Kovai Medical Center and Hospital Limited (KOVAI.BO)
Skylight Health Group Inc. (SLHG.V)
Srivichaivejvivat Public Company Limited (VIH.BK)
Natur International Corp. (NTRU)
Mycotopia Therapies, Inc. (TPIA)
Numinus Wellness Inc. (NUMIF)
Business
Apollo Hospitals Enterprise Limited operates as India's largest integrated private healthcare provider, delivering comprehensive hospital services, diagnostics, pharmacies, and digital health solutions through a network of over 70 hospitals with more than 10,000 beds across India and select international locations. Founded in 1983 and headquartered in Chennai, Tamil Nadu, the company offers tertiary care in over 50 specialties including cardiac sciences, oncology, neurosciences, orthopaedics, gastroenterology, and transplants; advanced diagnostics via Apollo Diagnostics with extensive imaging and pathology labs; retail pharmacy services through Apollo Pharmacy's 6,000-plus outlets; primary and secondary care under Apollo Health and Lifestyle encompassing Apollo Clinics, Apollo Sugar diabetes centers, Apollo White dental hospitals, Apollo Dialysis centers, Apollo Spectra surgical hospitals, Apollo Cradle women's and children's hospitals, and Apollo Fertility clinics; digital health platforms like Apollo 24/7 for telemedicine, online consultations, medicine delivery, and in-home diagnostics; and telehealth services via Apollo TeleHealth Services with franchised clinics and corporate wellness programs. Apollo Hospitals maintains a significant presence in major Indian cities and regions, targeting urban and semi-urban populations alongside international patients through medical tourism, with subsidiaries focused on research, education, and project consultancy. In September 2025, the company agrees to acquire International Finance Corporation's 31% stake in Apollo Health and Lifestyle for Rs 1,254 crore, making it a wholly owned subsidiary to sharpen focus on high-growth segments like primary care, diagnostics, birthing centers, and dialysis; it also inaugurates advanced facilities such as a state-of-the-art cath lab in Chennai and celebrates milestones including 600 pediatric liver transplants and 6,000 pediatric cardiac surgeries, while planning Rs 8,000 crore investments to add 4,300 beds over five years.